Literature DB >> 9281499

How lysophosphatidylcholine inhibits cell-cell fusion mediated by the envelope glycoprotein of human immunodeficiency virus.

S Günther-Ausborn1, T Stegmann.   

Abstract

We have investigated the effect of lysophosphatidylcholine (LPC) on fusion of cells expressing the envelope glycoprotein of HIV-1, gp120/gp41, with cells expressing the receptor for this virus, CD4. Fusion was inhibited by micromolar concentrations of LPC added from an aqueous stock solution, but not by membrane-associated LPC or LPC produced in the membrane by the action of phospholipase A2. No inhibition was found for LPCs with acyl chain lengths shorter than 12 carbon atoms, and the inhibitory effect of longer molecules increased with their length. gp120-CD4 specific cell-cell binding was inhibited with a chain length dependence corresponding to that of fusion, but with palmitoyl-LPC, fusion was more strongly affected than binding. These data indicate that gp120/gp41-induced fusion is inhibited by LPC because LPC affects viral protein-host cell binding and not because LPC prevented the formation of lipid intermediates required for fusion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9281499     DOI: 10.1006/viro.1997.8699

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Mass spectrometry reveals specific and global molecular transformations during viral infection.

Authors:  Eden P Go; William R Wikoff; Zhouxin Shen; Grace O'Maille; Hirotoshi Morita; Thomas P Conrads; Anders Nordstrom; Sunia A Trauger; Wilasinee Uritboonthai; David A Lucas; King C Chan; Timothy D Veenstra; Hanna Lewicki; Michael B Oldstone; Anette Schneemann; Gary Siuzdak
Journal:  J Proteome Res       Date:  2006-09       Impact factor: 4.466

3.  Surfactin Inhibits Membrane Fusion during Invasion of Epithelial Cells by Enveloped Viruses.

Authors:  Lvfeng Yuan; Shuai Zhang; Yongheng Wang; Yuchen Li; Xiaoqing Wang; Qian Yang
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

4.  Membrane fusion promoters and inhibitors have contrasting effects on lipid bilayer structure and undulations.

Authors:  T J McIntosh; K G Kulkarni; S A Simon
Journal:  Biophys J       Date:  1999-04       Impact factor: 4.033

5.  Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells.

Authors:  Michiko Mitsuishi; Seiko Masuda; Ichiro Kudo; Makoto Murakami
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

6.  Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment.

Authors:  J Bestman-Smith; J Piret; A Désormeaux; M J Tremblay; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells.

Authors:  D Fenard; G Lambeau; E Valentin; J C Lefebvre; M Lazdunski; A Doglio
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion.

Authors:  Xiaoxu Lin; Cynthia A Derdeyn; Robert Blumenthal; John West; Eric Hunter
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 9.  Mechanism of Membrane Fusion: Interplay of Lipid and Peptide.

Authors:  Ankita Joardar; Gourab Prasad Pattnaik; Hirak Chakraborty
Journal:  J Membr Biol       Date:  2022-04-18       Impact factor: 2.426

10.  Effect of membrane curvature-modifying lipids on membrane fusion by tick-borne encephalitis virus.

Authors:  Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.